In the phase 3 trial in patients with WHIM syndrome, treatment with CXCR4 antagonist mavorixafor increased and corrected peripheral blood CD4+ and CD8+ T-cell lymphopenia (32, 33). The gene discussed is CD8A; the disease is lymphopenia.